Moreover, compared to before treatment (1.41 ± 0.48 ng/mL), Hsp90-beta level in serum of patients with lung cancer also showed a decrease (1.33 ± 0.18 ng/mL) (P < 0.001) (Fig. 1d), but the decline was much less than that in MPE. Here, HSP90AB1 is linked to lung cancer.